20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hallucinogen Rating Scale (HRS) - Versão brasileira: tradução e adaptação transcultural Translated title: Hallucinogen Rating Scale (HRS) - A Brazilian version: translation and cross-cultural adaptation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          CONTEXTO: Existe um crescente interesse científico pelos efeitos de alucinógenos em geral e, particularmente, pelo uso religioso da bebida psicoativa ayahuasca no Brasil. Todavia, não há no Brasil um instrumento padronizado para avaliar os efeitos de alucinógenos. A Hallucinogen Rating Scale (HRS) é um questionário amplamente usado nos Estados Unidos e na Europa para avaliar os efeitos de diversas substâncias psicoativas, incluindo as alucinógenas. OBJETIVO: Traduzir e adaptar a HRS para o português brasileiro. MÉTODO: A adaptação foi realizada em três etapas: 1) os autores do artigo traduziram a HRS para o português, visando à elaboração de uma versão-síntese inicial; 2) foi feita retrotradução dessa versão para o inglês por dois tradutores independentes; 3) foi elaborada uma versão final em português brasileiro por um comitê de revisão. Esta versão final foi desenvolvida pela comparação entre as traduções iniciais e as retrotraduções, por um processo dialógico com o autor do instrumento. RESULTADOS: Produção da versão final da HRS em português. Observaram-se as diretrizes para equivalência semântica e conceitual entre o português e inglês na descrição de estados subjetivos induzidos por alucinógenos. CONCLUSÃO: Uma versão brasileira da HRS - instrumento largamente empregado em todo o mundo para quantificar os efeitos de psicoativos - fornece um instrumento sensível para a avaliação de efeitos de substâncias alucinógenas no Brasil.

          Translated abstract

          BACKGROUND: There is a growing scientific interest in the effects of hallucinogens in general and the religious use of psychoactive brew ayahuasca in Brazil in particular. However, there is not yet a standard instrument used in Brazil to evaluate the effects of hallucinogens. The Hallucinogen Rating Scale (HRS) is a questionnaire widely used in the U.S. and Europe to evaluate the effects of several psychoactive substances, including hallucinogens. OBJECTIVE: To translate and adapt the HRS to Brazilian Portuguese. METHOD: We followed three steps: 1) the authors of the article translated the HRS into Portuguese, in order to establish an initial version; 2) two independent translators back-translated this version into English; 3) a revision committee produced a final version of the Brazilian Portuguese version. This final version was developed comparing the initial translations and back-translations, through a dialogic process with the author of the instrument. RESULTS: A final Portuguese version of the HRS, following the guidelines for semantic and conceptual equivalence between English and Portuguese to describe hallucinogen-induced subjective states. DISCUSSION: A Brazilian version of the HRS - an instrument widely used throughout the world to quantify effects of psychoactive drugs - provides a sensitive instrument for evaluation of the effects of hallucinogenic substances in Brazil.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

          Although psilocybin has been used for centuries for religious purposes, little is known scientifically about its acute and persisting effects. This double-blind study evaluated the acute and longer-term psychological effects of a high dose of psilocybin relative to a comparison compound administered under comfortable, supportive conditions. The participants were hallucinogen-naïve adults reporting regular participation in religious or spiritual activities. Two or three sessions were conducted at 2-month intervals. Thirty volunteers received orally administered psilocybin (30 mg/70 kg) and methylphenidate hydrochloride (40 mg/70 kg) in counterbalanced order. To obscure the study design, six additional volunteers received methylphenidate in the first two sessions and unblinded psilocybin in a third session. The 8-h sessions were conducted individually. Volunteers were encouraged to close their eyes and direct their attention inward. Study monitors rated volunteers' behavior during sessions. Volunteers completed questionnaires assessing drug effects and mystical experience immediately after and 2 months after sessions. Community observers rated changes in the volunteer's attitudes and behavior. Psilocybin produced a range of acute perceptual changes, subjective experiences, and labile moods including anxiety. Psilocybin also increased measures of mystical experience. At 2 months, the volunteers rated the psilocybin experience as having substantial personal meaning and spiritual significance and attributed to the experience sustained positive changes in attitudes and behavior consistent with changes rated by community observers. When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences. The ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

            Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety. A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin. A clinical research unit within a large public sector academic medical center. Twelve adults with advanced-stage cancer and anxiety. In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment. Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance. This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field. clinicaltrials.gov Identifier: NCT00302744.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

              Psilocybin has been used for centuries for religious purposes; however, little is known scientifically about its long-term effects. We previously reported the effects of a double-blind study evaluating the psychological effects of a high psilocybin dose. This report presents the 14-month follow-up and examines the relationship of the follow-up results to data obtained at screening and on drug session days. Participants were 36 hallucinogen-naïve adults reporting regular participation in religious/ spiritual activities. Oral psilocybin (30 mg/70 kg) was administered on one of two or three sessions, with methylphenidate (40 mg/70 kg) administered on the other session(s). During sessions, volunteers were encouraged to close their eyes and direct their attention inward. At the 14-month follow-up, 58% and 67%, respectively, of volunteers rated the psilocybin-occasioned experience as being among the five most personally meaningful and among the five most spiritually significant experiences of their lives; 64% indicated that the experience increased well-being or life satisfaction; 58% met criteria for having had a 'complete' mystical experience. Correlation and regression analyses indicated a central role of the mystical experience assessed on the session day in the high ratings of personal meaning and spiritual significance at follow-up. Of the measures of personality, affect, quality of life and spirituality assessed across the study, only a scale measuring mystical experience showed a difference from screening. When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                rpc
                Archives of Clinical Psychiatry (São Paulo)
                Arch. Clin. Psychiatry (São Paulo)
                Faculdade de Medicina da Universidade de São Paulo (São Paulo )
                1806-938X
                2011
                : 38
                : 6
                : 231-237
                Affiliations
                [1 ] Universidade Federal de São Paulo Brazil
                [2 ] Universidade Estadual de Santa Cruz Brazil
                [3 ] da Universidade do Novo México
                Article
                S0101-60832011000600004
                10.1590/S0101-60832011000600004
                cd6a0818-d0ff-4f86-b26e-31620700df3a

                http://creativecommons.org/licenses/by/4.0/

                History
                Product

                SciELO Brazil

                Self URI (journal page): http://www.scielo.br/scielo.php?script=sci_serial&pid=0101-6083&lng=en
                Categories
                MEDICINE, GENERAL & INTERNAL
                PSYCHIATRY

                Internal medicine,Clinical Psychology & Psychiatry
                Ayahuasca,hallucinogens,dimethyltryptamine,scales,validation,alucinógenos,dimetiltriptamina,escalas,validação

                Comments

                Comment on this article